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Based on U.S. claims data, we assigned doctors IDs based on the physician who treated 
the enrollee for the longest period of time after eliminating any emergency room, labo-
ratory, and radiology services. Physician prescribing patterns were then calculated 
from prescription drug records. Patients were grouped as generic SSRIs, non-generic 
SSRIs, and SNRIs. RESULTS: We identiﬁed the doctors’ prescribing pattern with the 
percentage of time they prescribed SSRIs, non-generic SSRIs and SNRIs. We showed 
that patients were more likely to be prescribed generic SSRIs relative to non-generic 
SSRIs if doctors’ prescribing patterns favored generic prescription (p = 0.000). Simi-
larly, patients were less likely to be in the SSRIs group if doctors’ prescribing patterns 
favored SNRI prescription (p = 0.000). CONCLUSIONS: Doctors’ prescribing pat-
terns are important factors for decisions on treatment. Any outcomes models (compli-
ance, or treatment effect on health care utilization and cost) should control for these 
patterns.
PMH92
TIME SERIES ANALYSIS TO EXAMINE THE EFFECT OF GUIDELINES
Baser O1, Yuce H2
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research / City University of New York, Ann Arbor, MI, USA
OBJECTIVES: Application of a segmented times series model to measure the effect of 
guidelines on outcomes measures. METHODS: To isolate the effect of guidelines, we 
need to control for three different factors: 1) Baseline differences between the two 
groups, 2) Step-wise differences at the intervention point, and 3) Trend differences 
after the intervention. The segmented times series model was combined with the 
propensity score matching technique. The segmented time series model contained two 
predictor variables: the binary intervention variable and an interval coding for time. 
The kitchen sink approach was used for propensity score matching and the segmented 
time series model controlled for the confounding inﬂuence of any underlying trend. 
The ﬁnal model ensured that any estimated change in the mean level of the series after 
intervention was not simply due to the series’ trend. RESULTS: Using U.S. claims data, 
we analyzed the effect of the American Psychiatric Association’s consensus statement 
on glucose monitoring for patients on atypical antipsychotic drugs. Glucose screening 
rose 1% per quarter among antipsychotic-treated patients before release of the guide-
lines, compared to 0.5% per quarter after (P = 0.005 for trend). Monitoring rates 
were 16.07% before release of the guidelines and 18.76% after (P < 0.001). CONCLU-
SIONS: The segmented time series model can provide a clear picture about both trend 
and intervention effect when analyzing the effects of guidelines.
PMH93
AGREEMENT BETWEEN PATIENTS WITH MILD DEMENTIA AND 
CAREGIVERS ON THE PROMIS CAT MEASURE OF PERCEIVED 
COGNITIVE FUNCTION
Nerenz DR, Pietrantoni L, Schultz L, Garden B, Shatz R
Henry Ford Hospital, Detroit, MI, USA
OBJECTIVES: The PROMIS measure of Perceived Cognitive Function has gone 
through multiple cycles of development and validation testing, but has not been 
extensively tested in clinical settings, particularly among patients being treated for 
neurological conditions and/or cognitive deﬁcits. We sought to do an initial examina-
tion of the extent to which patients being treated for mild dementia and their caregiv-
ers would agree in their assessment of patient cognitive function using the PROMIS 
PCF measure. METHODS: A total of 14 consecutive patients being seen in the Neurol-
ogy outpatient clinic at Henry Ford Hospital for a diagnosis of dementia, as well as 
one adult caregiver per patient, were invited to complete the PROMIS Perceived 
Cognitive Function CAT measure in reference to the patient’s current level of cognitive 
function. Several analyses of agreement between caregiver and patient reports were 
conducted. RESULTS: All patients and all caregivers were able to successfully com-
plete the PROMIS PCF measure. There was no signiﬁcant difference between patients 
and caregivers in either mean raw score, mean T-score, or standard error for the 
measure. The score ranges for caregivers and patients were quite comparable. The 
Pearson correlation coefﬁcients for association between patient and caregiver 
responses were .246 and .286 for raw score and t-score, respectively (both n.s.). 
CONCLUSIONS: The lack of signiﬁcant difference between patients and caregivers 
on mean response suggests possible validity of the PCF measure for group-level analy-
ses, but the relatively low correlations between patient and caregiver suggest caution 
about use of the measure at the individual patient level. The next step of analysis will 
involve comparison of patient PCF scores to scores on objective measures of cognitive 
function.
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
PMS1
ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID 
ARTHRITIS (RA)—FINDINGS FROM A RETROSPECTIVE CLAIMS 
DATABASE ANALYSIS USING A PRE-PROGRAMMED DATA ANALYSIS 
TOOL
Chiappinelli R1, McNeeley B1, Byrd J2, Ollinger E2
1HealthCore, Wilmington, DE, USA, 2Dymaxium Inc, Toronto, ON, Canada
OBJECTIVES: RA is a systemic disease resulting in comorbidities that affect quality 
of life, prognosis and outcomes. Comorbid illnesses can impact treatment, medical 
costs, disability and risk of mortality. Rheumatoid Arthritis Outcomes Analyzer, a 
validated claims data analysis tool with a user-friendly interface was used to character-
ize comorbidities in patients with RA. METHODS: The study included patients age 
18 or older with at least 2 diagnoses of RA (ICD-9 CM 714.0X) ≥ 2 months apart 
between January 2005 and December 2007 from the HealthCore Integrated Research 
DatabaseSM. Patients must have received ≥ one traditional (non-biologic) or biologic 
DMARD medication with RA diagnoses at least two months apart. All medical and 
pharmacy claims were entered into the ﬁnal dataset. RESULTS: A total of 25,856 RA 
patients entered into the analysis (mean age = 56; 74.8% female). The overall mean 
Charlson Comorbidity Index (CCI) was 2.00 (SD = 1.63) and was higher for males 
(mean = 2.18; SD = 1.85) than females (mean = 1.94; SD = 1.55). In the 18 to 44 age 
group, females tended to have a higher CCI (mean = 1.38; SD = 0.91) than males 
(mean = 1.30; SD = 0.81). This trend reverses in older patients where the mean CCI 
in males in the 45 to 64 and ≥ 65 age groups is 1.90 (SD = 1.50) and 3.31 (SD = 2.39) 
respectively versus 1.76 (SD = 1.29) and 2.80 (SD = 2.07) in females. The most fre-
quent comorbid conditions for all patients were; chronic pulmonary disease, diabetes, 
cerebrovascular disease, tumor, congestive heart failure, peripheral vascular disease 
and renal disease. CONCLUSIONS: This analysis explores and differentiates the CCI 
by gender and age group in patients with RA using a validated claims data analysis 
tool. Further study will examine the relationship between comorbidity and health-
related and cost outcomes.
PMS2
ESTIMATING HEALTH-RELATED UTILITY FROM CLINICALLY ASSESSED 
DISEASE SEVERITY IN ANKYLOSING SPONDYLITIS
Poole CD1, Singh A2, Freundlich B3, Koenig A3, Currie CJ4
1Pharmatelligence, Cardiff, UK, 2Pﬁzer, Philadelphia, PA, USA, 3Pﬁzer, Collegeville, PA, USA, 
4Cardiff University, Cardiff, Wales, UK
OBJECTIVES: We sought to conduct a statistical mapping analysis between a stan-
dard investigator assessment of disease severity in ankylosing spondylitis (AS) and 
domain responses in a standard index of health utility; and secondly, to implement 
the above mapping in an optimised algorithm to estimate utility. METHODS: Multi-
nomial logistic regression was used to estimate response probabilities to each domain 
of the EQ5D from the Bath Ankylosing Spondylitis Metrology Index (BASMI) among 
patients enrolled into an RCT studying the use of either etanercept infusion vs. oral 
sulphasalazine (ASCEND). Other covariates tested were gender, age, co-morbidity, AS 
duration, DMARD history, and concurrent medications. Predicted EQ5Dindex was 
estimated by Monte Carlo bootstrap simulation. The predictive ability of the response 
mapping was assessed by comparing estimated and directly measured utility derived 
from the UK tariff. RESULTS: Evaluable data were available for 566 predominantly 
white (87%) patients, 74% of whom male, with a mean baseline age of 41 years (sd 
12) and median AS duration 4 years (IQR 1 to 11). Average BASMIlinear was 4.1 (sd 
1.8) whilst median observed EQ5D utility was 0.587 (IQR 0.193 to 0.691). The linear 
deﬁnition of the BASMI was optimal in an algorithm that also adjusted for gender, 
AS duration, number of co-morbid body systems, number of historic DMARDs, 
number of current non-DMARD drugs, and current NSAID use. The mean utility 
predicted by the optimized algorithm was 0.552 (sd 0.101) and 0.559 (sd 0.295) by 
estimation directly from EQ5D responses (p = 0.238). The mean squared error 
between the actual and predicted utilities was 0.076 (sd 0.111). Adjusted utility was 
deﬁned by −0.044*BASMIlinear+0.715, with an R2 of 0.62. CONCLUSIONS: In this 
study, response mapping of AS disease activity to the EQ5Dindex produced reliable 
estimates of preference-based health-related utility. Future analysis will compare the 
relative ability of patient-reported, AS-speciﬁc, functional assessment measures in 
predicting health-related utility.
PMS3
A BAYESIAN ANALYSIS OF BISPHOSPHONATE EFFICACY FOR THE 
TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
Malone DC1, Hansen GL2, Sorensen L2
1University of Arizona, Tucson, AZ, USA, 2University of Copenhagen, Copenhagen, 
Denmark
OBJECTIVES: The aim of this study was to evaluate the effectiveness of ﬁve bisphos-
phonates approved for the treatment of postmenopausal osteoporosis. METHODS: 
Randomized placebo controlled studies describing the occurrence of clinical vertebral 
(CVF), morphometric vertebral (MVF) and nonvertebral fractures (NVF) were identi-
ﬁed by searching the Cochrane Database, International Pharmaceutical Abstracts and 
Ovid Medline. Studies were eligible if patients had suffered a fracture at entry or had 
a bone mineral density at least 2 SD below the mean value for young adult females. 
WinBUGS was used to conduct the analysis, which permitted combining direct and 
indirect evidence to rank order the treatments. RESULTS: A total of 39 studies were 
identiﬁed. All ﬁve bisphosphonates were found to reduce the relative risk of new 
fractures in women with postmenopausal osteoporosis. For CVF, all ORs for treat-
ments compared to placebo were statistically signiﬁcant, suggesting that treatment 
with any agent is better than none. Zoledronate was the most effective treatment (OR 
= 0.22, 95%CRI:0.13–0.36), followed by both alendronate (OR = 0.48, 95%CRI:0.30–
0.76) and ibandronate (OR = 0.51, 95%CRI:0.34–0.77) as these could not be dif-
ferentiated statistically (no data were available for etidronate and risedronate). For 
MVF also, all ORs for treatments compared to placebo were statistically signiﬁcant. 
Zoledronate (OR = 0.28, 95%CRI:0.22–0.35) and etidronate (OR = 0.29, 
95%CRI:0.17–0.48) were both most effective, followed by alendronate (OR = 0.52, 
95%CRI:0.42–0.64), risedronate (OR = 0.56, 95% 0.45–0.70) and ibandronate (OR 
= 0.67, 95% 0.54–0.83); The last three could not be differentiated. For NVF the ORs 
for zoledronate (OR = 0.70, 95%CRI:0.60–0.80), risedronate (OR = 0.71, 
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95%CRI:0.58–0.88) and alendronate (OR = 0.80, 95%CRI:0.70–0.91) compared to 
placebo were statistically signiﬁcant, while those for ibandronate (OR = 0.91, 
95%CRI:0.41–2.09) and etidronate (OR = 0.95, 95%CRI:0.44–2.12) were not. When 
the treatments were compared directly to each other, none of the treatments were 
statistically more effective than others. CONCLUSIONS: Overall, zoledronate 
appeared to be most effective at reducing fractures in women with postmenopausal 
osteoporosis.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
PMS4
CHARACTERIZING UNCERTAINTY IN EARLY-DEVELOPMENT 
BUDGETARY IMPACT MODELS: A CASE STUDY OF DENOSUMAB
Taylor DC1, Clements K1, Emptage NP1, Tao CY1, Viswanathan HN2, Yurgin N2, 
Weinstein MC3
1i3 Innovus, Medford, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Harvard School of 
Public Health, Boston, MA, USA
OBJECTIVES: Budgetary impact modeling often occurs early, amidst uncertainty 
surrounding the eligible patient population or the ﬁnal price of a new intervention. 
Uncertainty can be characterized using per-member per-month (PMPM) iso-curves 
that graphically depict the net budgetary impact at different prices and population 
sizes. The objective of this study is to examine the use of PMPM budgetary impact 
(PMPMBI) iso-curves to represent budgetary uncertainty for products prior to regula-
tory approval, using denosumab as an example. METHODS: A 3-year Markov cohort 
budgetary impact model (BIM) was developed for denosumab in the treatment of 
postmenopausal osteoporosis in a hypothetical US managed care plan. The model 
incorporates current market shares and persistence on osteoporosis treatments, and 
calculates the net impact of adding denosumab to the health plan. Direct costs include 
drug costs and medical cost offsets due to reductions in osteoporotic fractures. The 
model was used to construct PMPMBI iso-curves for each of the 3 model years by 
systematically varying the price of denosumab and the number of patients receiving 
treatment while holding all other parameters constant. RESULTS: In year 1, the 
PMPMBI iso-curves ranged from $−0.06 to $0.08 using the lower and upper limits 
of price and population size assumptions. The lower iso-curves occur at lower prices 
and/or population sizes and vice versa. Budget impact is insensitive to the size of the 
patient population when the price of denosumab is equal to the weighted average price 
of all other interventions. CONCLUSIONS: Iso-curves can be used to concisely report 
BIM results over a wide range of price and population size assumptions. The budgetary 
impact of denosumab can easily be interpolated once price and population size are 
known, allowing decision-makers to estimate PMPM costs soon after product 
approval.
PMS5
MEDICAL COSTS FOLLOWED BY FALLS/SLIPS AT A TEACHING 
HOSPITAL IN JAPAN
Egami K1, Hirose M1, Tsuda Y1, Ohama K1, Honda J1, Shima H1, Oh EH2
1Saint Mary’s Hospital, Kurume, Japan, 2Hyupsung University, Hwaseong, South Korea
OBJECTIVES: Medical costs followed by incidents within hospitals are not linked 
with primary diseases and might be paid by hospitals. In that manner, it is very 
important for hospital managers to recognize the actual situation of medical costs for 
incidents. Cases injured with over the level two and their medical costs for a year are 
explored. METHODS: There are 2,866 incident reports in 2007 collected at Saint 
Mary’s Hospital in Kurume-City, Fukuoka, Japan. Their reports include 734 cases for 
Falls/Slips and 2,132 cases for others. The cases for Falls/Slips are classiﬁed 474 with 
level 1, 320 with level 2, and 136 with level 3a, and 14 with level 3b, respectively. 
Of the 14 cases with level 3a included three femoral neck fractures and femoral tro-
chanteric fractures each, and one femoral shaft fracture, facial fracture, clavicle frac-
ture, shoulder fracture, upper extremity fracture, lower extremity fracture, thoracic 
vertebral fracture, and traumatic subarachnoid hemorrhage,each. RESULTS: Accord-
ing to the injury level, average medical costs are 88 dollars (level 2, 59 cases), 94 
dollars (level 3a, 86 cases), and 12,330 dollars (level 3b, 14 cases). Medical costs with 
level 2 and 3a are directly calculated from the medical fee schedule under the social 
insurance system. By contrast, medical costs with level 3b are alternated by the average 
medical fee of the same diseases at the hospital, because we can not separate medical 
costs for injury by incidents and for primary diseases. For example, averaged medical 
cost for femoral neck fracture is 18,400 dollars by calculating 182 cases with same 
diseases were treated at our hospital. CONCLUSIONS: Total amount of medical costs 
for Falls/Slips is about 19 million dollars at our hospital for the year of 2007. There-
fore, Hospital administrators have to take appropriate measures to prevent patients 
from Falls/Slips and save money, because this amount is not overlooked.
PMS6
COMPARISON OF COST OF ALLOPURINOL VS FEBUXOSTAT AS A 
FIRST LINE TREATMENT FOR GOUT
Jutkowitz E1, Pizzi L2, Meltzer M3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Jefferson School of Population Health, 
Philadelphia, PA, USA, 3Thomas Jefferson University Hospital, Philadelphia, PA, USA
OBJECTIVES: The objective of this study was to build a decision analytic model to 
estimate the cost and effectiveness of allopurinol 300 mg/d and febuxostat 80 mg/d 
as a ﬁrst line treatment for gout patients based on available clinical and cost data. 
METHODS: We built a decision analytic model as a decision tree using TreeAge Pro 
2009, in which allopurinol was compared to febuxostat as a ﬁrst line treatment for 
gout. The model examined two time horizons: 1–8 weeks and 9–52 weeks. Treatment 
success from week 1–8 was deﬁned as no case of gout ﬂare. If a gout ﬂare occurred 
within week 1–8 there was an equal chance of continuing on treatment or switching 
to the alternative treatment strategy during weeks 9–52. During weeks 9–52 treatment 
failure occurred with report of a gout ﬂare. Treatment failure due to gout ﬂare was 
assumed to result in an additional physician visit. Costs of adverse events (musculo-
skeletal, joint-related signs and symptoms, liver function test abnormalities) from 
treatment were accounted for and assumed to result in a doctor visit. Data used to 
construct the economic model were derived from published clinical trials as well as 
available sources of physician and drug costs. Sensitivity analyses were preformed to 
assess the impact of variations on all model inputs. RESULTS: Total cost of allopu-
rinol as a ﬁrst line treatment for gout was $1125 compared to $7737 for febuxostat 
as a ﬁrst line treatment for gout. Sensitivity analyses indicate the model is most sensi-
tive to pill price. All else equal, a monthly supply of febuxostat would need to cost 
less then $3 to be as cost-effective as allopurinol. CONCLUSIONS: Allopurinol was 
$6612 less as a ﬁrst line treatment compared to febuxostat and therefore the cost 
effective treatment and as such should remain a ﬁrst line treatment.
PMS7
COST ANALYSIS OF RECENTLY APPROVED AND OLDER ANTI-TNF 
BIOLOGIC AGENTS USED IN RHEUMATOID ARTHRITIS
Carter C, Schmeichel-Mueller C, McKenzie RS, Piech CT
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
OBJECTIVES: Historical comparative cost analyses have included adalimumab 
(ADA), etanercept (ETA), and inﬂiximab (IFX). More recently, certolizumab pegol 
(CTP) and golimumab (GLM) have been FDA-approved for use in RA. The objective 
of this analysis was to estimate and compare annual drug and treatment costs of all 
anti-TNF agents approved for use in RA based on FDA-approved prescribing informa-
tion. METHODS: A cost analysis was conducted using FDA-approved prescribing 
information to calculate cumulative dose and administration schedule over a 12-month 
time horizon. Wholesale acquisition costs were obtained from First Databank for 
December 2009, with annual costs computed using labeled dosing. ADA cost was 
based on 26 injections of 40 mg every other week. CTP cost was calculated based on 
15 injections of 400 mg (weeks 0, 2, and 4 loading doses and 400 mg every 4 weeks 
maintenance dosing). ETA cost was based on 52 injections of 50 mg once weekly. 
GLM cost was based on 12 injections of 50 mg once monthly. IFX cost was calculated 
based on 100 mg vials for initial dosing of 3 mg/kg (75 kg patient) with dose increase 
to 5 mg/kg at 6 months (weeks 0, 2, and 6 loading doses with every 8 week mainte-
nance infusions; infusion fee = $181.05 per infusion from 2009 CMS Physician Fee 
Schedule). Costs of adverse events and concomitant methotrexate were assumed 
equivalent across all agents. A sensitivity analysis was conducted to assess impact of 
average sales price (ASP) on results. RESULTS: Annual drug only costs were $19,812 
(ADA), $21,940 (CTP), $20,190 (ETA), $19,824 (GLM), and $16,306 (IFX). Includ-
ing administration fees for infusion, the annual treatment cost of IFX was $17,754. 
A sensitivity analysis using ASP + 6% yielded similar results. CONCLUSIONS: Annual 
treatment costs of anti-TNF agents, including newer agents, are comparable when 
used for RA patients according to label.
PMS8
HIGH-COST MEDICATIONS IN 10 COUNTRIES: A CROSS-SECTIONAL 
COMPARATIVE STUDY
Canon O, Daza L, Gomez J, Moreno I, Castillo C, Rodriguez J
Fundacion Salud y Equidad, Bogota, Bogota, Colombia
OBJECTIVES: To compare, between European and Latin American countries, the list 
prices of brands for the most expensive drugs in Colombia (Imatinib, Abacavir + 
Zidovudine + Lamivudine, Docetaxel, Etanercept, Filgrastim, Gemcitabine, Inﬂix-
imab, Interferon Beta 1 A, Interferon Beta1 B, Leuprolide, Lopinavir + Ritonavir, 
Mycophenolate, Octreotide, Paclitaxel, Somatotropin and Temozolamide). 
METHODS: We searched for list prices of the 16 most expensive drugs, as charged 
to the Colombian state, from 21 manufacturers in 10 countries. In Europe: Belgium, 
Spain and the UK were analyzed, while in Latin America: Chile, Colombia, Ecuador, 
Paraguay, Peru and Uruguay were studied. For the data analysis, UK list prices were 
used as the standard. RESULTS: For comparison purposes, we selected 21 manufac-
turers offering these high-cost medications in the 10 countries analyzed, leading to a 
pool of 210 potential market prices. Out of them, 142 were obtained (we had the 21 
for the UK). A total of 101 prices (71.1%) are higher than those in the UK. Average 
prices are 168.5% (SD0.99) of the UK price. The average for Latin American countries 
was 197.4% (SD1.13) of the UK price, and 118.6% (SD 0.31) for the European 
countries. The country with the highest average is Uruguay (294.7% UK price, 
SD0.95), followed by Colombia (278.5% UK price, SD1.13). The country with the 
lowest average is our standard, the UK (SD 100.0%), followed by Ecuador (105.1% 
UK price, SD 0.4). CONCLUSIONS: We found a signiﬁcant difference between 
average prices in Europe and Latin America, the latter being much higher than the 
UK standards. If UK prices were used in Latin America, it would be possible to treat 
twice as many patients as are currently treated. In Colombia, based on the information 
available, around US$ 67 Million could be saved if UK prices were charged, assuming 
that purchases are made at list prices.
